2,950 results match your criteria: "Antoni Van Leeuwenhoek Hospital[Affiliation]"

Prognostic and Predictive Biomarkers of Oligometastatic NSCLC: New Insights and Clinical Applications.

JTO Clin Res Rep

December 2024

Department of Pulmonary Diseases, GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, The Netherlands.

This review discusses the current data on predictive and prognostic biomarkers in oligometastatic NSCLC and discusses whether biomarkers identified in other stages and widespread metastatic disease can be extrapolated to the oligometastatic disease (OMD) setting. Research is underway to explore the prognostic and predictive value of biological attributes of tumor tissue, circulating cells, the tumor microenvironment, and imaging findings as biomarkers of oligometastatic NSCLC. Biomarkers that help define true OMD and predict outcomes are needed for patient selection for oligometastatic treatment, and to avoid futile treatments in patients that will not benefit from locoregional treatment.

View Article and Find Full Text PDF

Background: The 313-variant polygenic risk score (PRS) provides a promising tool for clinical breast cancer risk prediction. However, evaluation of the PRS across different European populations which could influence risk estimation has not been performed.

Methods: We explored the distribution of PRS across European populations using genotype data from 94,072 females without breast cancer diagnosis, of European-ancestry from 21 countries participating in the Breast Cancer Association Consortium (BCAC) and 223,316 females without breast cancer diagnosis from the UK Biobank.

View Article and Find Full Text PDF

Advances in cancer treatments have significantly improved their effectiveness, yet access to first-line therapies remains limited. A 2017 survey revealed that over 25 % of metastatic melanoma patients in Europe lacked access to recommended therapies. To address this, the European Association of Dermato-Oncology and the European Melanoma Registry conducted a follow-up study on the registration and reimbursement of first-line treatments.

View Article and Find Full Text PDF

Background: Patients receiving intraoperative ventilation during general anesthesia often have low end-tidal CO (etCO). We examined the association of intraoperative etCO levels with the occurrence of postoperative pulmonary complications (PPCs) in a conveniently-sized international, prospective study named 'Local ASsessment of Ventilatory management during General Anesthesia for Surgery' (LAS VEGAS).

Methods: Patients at high risk of PPCs were categorized as 'low etCO' or 'normal to high etCO' patients, using a cut-off of 35 mmHg.

View Article and Find Full Text PDF

Introduction And Objective: Imiquimod (IQ) is an immunomodulator used in the management of penile intraepithelial neoplasia (PeIN) lesions. However, IQ treatment may be associated with bothersome side effects (SEs). To date, studies reporting on this morbidity and evaluating predictors of response to IQ are scarce and included small cohorts.

View Article and Find Full Text PDF

Introduction: Health-related quality of life (HRQoL) is emerging as an endpoint, adjunct to survival, in cancer treatment. For this reason, the European Organization for Research and Treatment of Cancer (EORTC) has developed standardized quality-of-life questionnaires to collect patient-reported outcome measurement (PROM), which so far have been widely used in clinical trials to evaluate the impact of new drugs on cancer patients. However, while these questionnaires comprehensively describe patient functions, little is known about their association with patient characteristics.

View Article and Find Full Text PDF

Win Ratio approach for the composite outcome of postoperative pulmonary complications: Secondary analysis of a harmonised and pooled database of three randomised clinical trials.

Eur J Anaesthesiol

December 2024

From the Australian and New Zealand Intensive Care Research Centre (ANZIC-RC), Monash University (ASN), Department of Intensive Care Austin Hospital, Melbourne, Australia (ASN), Department of Critical Care Medicine, Hospital Israelita Albert Einstein (ASN, NSC), Pulmonary Division, Cardio-Pulmonary Department, Instituto do Coração, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidad de de Sao Paulo, Sao Paulo, Brazil (ASN), Pulmonary Engineering Group, Department of Anesthesiology and Intensive Care Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany (TB, MgdA), Department of Anaesthesiology The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (SNTH), Department of Anesthesiology Amsterdam University Medical Centers, location 'AMC', Amsterdam, the Netherlands (SNTH), Department of Anesthesiology and Critical Care, Hospital Clinic de Barcelona, Institut D'investigació August Pi i Sunyer, Barcelona (CF), CIBER (Center of Biomedical Research in Respiratory Diseases), Instituto de Salud Carlos III, Madrid (CF), Navarrabiomed-Fundación Miguel Servet, Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Pamplona (JL), Anesthesia and Critical Care Department, Hospital IMED Valencia, Valencia, Spain (MS), IRCCS San Martino Policlinico Hospital (LB), Department of Surgical Sciences and Integrated Diagnostics (DISC), University of Genoa, Genoa, Italy (LB), Department of Anesthesiology and Pain Medicine, Hospital Universitario y Politécnico la Fe (GM), Perioperative Medicine Research Group, Instituto de Investigación Sanitaria la Fe (GM), Department of Statistics and Operational Research, Universidad de Valencia, Valencia, Spain (GM), Division of Intensive Care and Resuscitation, Outcomes Research Consortium, Division of Cardiothoracic Anesthesia, Integrated Hospital Care Institute, Cleveland Clinic, Cleveland, Ohio, USA (MGdA), Department of Intensive Care, Amsterdam University Medical Centers, location 'AMC', Amsterdam, the Netherlands (MS), Mahidol University, Bangkok, Thailand (MS), Mahidol Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand (MS) and Nuffield Department of Medicine, University of Oxford, Oxford, UK (MS).

Background: The win ratio analysis method might provide new insight on the impact of positive end-expiratory pressure (PEEP) on clinical outcomes.

Objective: The aim is to re-analyse the results of the 'Re-evaluation of the effects of high PEEP with recruitment manoeuvres vs. low PEEP without recruitment manoeuvres during general anaesthesia for surgery' (REPEAT) study using the win ratio analysis.

View Article and Find Full Text PDF

Population-based screening programs aim to detect the disease at an early stage, so less treatment will be needed as well as having better oncological outcomes when diagnosed earlier. In the majority of European countries, breast cancer screening programs are designed based on women age.Meta-analysis of randomized clinical trial data demonstrates a reduction in the relative risk of breast cancer mortality due to screening, which has been estimated to be approximately 20%.

View Article and Find Full Text PDF

Upper age limits are currently fixed for all fecal immunochemical test (FIT)-based colorectal cancer (CRC) screening programs. A risk-stratified upper age limit may be beneficial. Therefore, we assessed differences in interval CRC risk among individuals who had reached the upper age limit of screening (75 years).

View Article and Find Full Text PDF

Purpose: We aimed to identify metastatic breast cancer (MBC) patients' preferences for exercise programs and identify patients' characteristics associated with these preferences, to facilitate implementation of exercise programs for MBC patients.

Methods: We used data from a multinational cross-sectional survey conducted among MBC patients. Patients reported their preferred exercise frequency, intensity, type, session duration, and supervision mode.

View Article and Find Full Text PDF

Perform early economic evaluation comparing active surveillance (AS) to surgery for women with low-risk ductal carcinoma , a precursor of invasive breast cancer. A 10-year incremental costs (€) and quality-adjusted life years (QALYs) were compared between a simulated cohort of women undergoing breast conserving surgery ± radiotherapy, and a cohort with a low-risk subgroup undergoing AS using a semi-Markov model. Scenario and headroom analyses evaluated a better-performing biomarker to select low-risk women for AS.

View Article and Find Full Text PDF

Less is more: The benefits of reduced follow-up in gynecologic cancers.

Gynecol Oncol

December 2024

Department of Medical and Clinical Psychology, CoRPS - Center of Research on Psychology in Somatic Diseases, Tilburg University, Warandelaan 2, 5037 AB Tilburg, the Netherlands; Department of Research, Netherlands Comprehensive Cancer Organization (IKNL), Boven Clarenburg 2, 3511 CV Utrecht, the Netherlands.

View Article and Find Full Text PDF

Prevalence and impact of vulvar lesions diagnosed prior to vulvar squamous cell carcinoma: A population-based cohort study.

Gynecol Oncol

December 2024

Amsterdam UMC location Vrije Universiteit Amsterdam, Pathology, De Boelelaan 1117, Amsterdam, the Netherlands; Cancer Centre Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands. Electronic address:

Objective: To systematically explore vulvar pathology diagnosed prior to vulvar squamous cell carcinoma (VSCC), as well as the association with tumor characteristics, stage and survival outcome, with the aim of improving vulvar cancer prevention strategies.

Methods: VSCC diagnosed between 2005 and 2019 were identified from a population-based cohort provided by the Dutch Nationwide Pathology Databank. Pathology reports were reviewed to identify vulvar pathology diagnosed before primary VSCC.

View Article and Find Full Text PDF

Measurement variability of radiologists when measuring brain tumors.

Eur J Radiol

December 2024

Department of Radiology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands; GROW - Research Institute for Oncology & Reproduction, Maastricht University, Maastricht, the Netherlands. Electronic address:

Background: In oncology trials, response evaluation criteria are pivotal in developing new treatments. This study examines the influence of measurement variability in brain lesions on response classification, considering long-standing cut-offs for progression and response were determined before the era of submillimeter resolutions of medical imaging.

Methods: We replicate a key study using modern radiological tools.

View Article and Find Full Text PDF

Background: Differentiating benign anterior mediastinal cysts from malignancies is challenging in clinical practice. International guidelines on optimal diagnostics and treatment for anterior mediastinal cystic lesions are lacking. The first part of the DETECTION project focuses on possible heterogeneity in diagnostics and treatment of anterior mediastinal cystic lesions among international thoracic medical experts.

View Article and Find Full Text PDF

Tumors escape immune detection and elimination through a variety of mechanisms. Here, we used prostate cancer as a model to examine how androgen-dependent tumors undergo immune evasion through downregulation of the major histocompatibility complex class I (MHCI). We report that response to immunotherapy in late-stage prostate cancer is associated with elevated MHC expression.

View Article and Find Full Text PDF
Article Synopsis
  • The European Cancer Organisation's Essential Requirements for Quality Cancer Care (ERQCC) provide guidance on how to improve cancer treatment, focusing on ovarian cancer specifically.
  • Ovarian cancer patients experience low cure rates due to inconsistent treatment and a need for specialized care, which should be provided in dedicated centers by qualified professionals.
  • Centralized, patient-centered care throughout the entire treatment journey is essential for better outcomes but is not yet widely implemented across many European countries.
View Article and Find Full Text PDF

Novel Methods to Assess Tumor Burden and Minimal Residual Disease in Genitourinary Cancers.

Eur Urol

December 2024

Department of Cancer Medicine and INSERM U981, Université Paris-Sud, Université Paris-Saclay, Gustave Roussy, Villejuif, France.

Article Synopsis
  • Advances in molecular diagnostics are transforming how prostate, renal, and urothelial cancers are assessed, offering more accurate detection methods for disease burden and minimal residual disease (MRD).
  • A literature review from 1980-2024 highlights emerging radiographic and molecular tools aimed at improving disease quantification and monitoring through innovative technologies and biomarker-informed trials.
  • New developments, like novel radiotracers and molecular detection methods (e.g., circulating tumor DNA), provide insights into disease mechanisms and have the potential to enhance clinical management, although full MRD application is still in progress.
View Article and Find Full Text PDF

Capturing the true effect of anti-PD-1 therapy on patients' health-related quality of life.

Lancet Oncol

December 2024

Department of Medical and Clinical Psychology, Center of Research on Psychological and Somatic Disorders, Tilburg University, Tilburg, Netherlands.

View Article and Find Full Text PDF

Purpose: To evaluate general practitioners' (GPs) experiences with providing cancer survivorship care and explore readiness for implementation.

Methods: This cross-sectional survey study was nested within two randomized-controlled trials conducted in the Netherlands between 2015 and 2023, comparing GP- with specialist-led survivorship care for patients with colon or prostate cancer. An adapted version of the normalisation measure development (NoMAD) survey was distributed among participating GPs.

View Article and Find Full Text PDF
Article Synopsis
  • Intravesical recurrence of upper tract urothelial carcinoma after radical nephroureterectomy occurs in 22% to 47%, prompting the need for effective intravesical chemotherapy, which remains underused due to safety and efficacy concerns.
  • A systematic review analyzed 18 studies with 2,483 patients, finding that intravesical chemotherapy significantly lowered the risk of recurrence at 12 months (OR=0.46) and 24 months (OR=0.41) after surgery.
  • The study highlighted a favorable safety profile for intravesical chemotherapy, showing only 9% minor and 0.9% major complications, while the optimal instillation methods require further investigation.
View Article and Find Full Text PDF

Background: The invasive nature of extended pelvic lymph node dissection (ePLND) prompts the need for alternative lymphatic mapping technologies. To change the focus to "sparing nodes that are not involved," the first step is to research the feasibility of intraoperatively distinguishing the lymph drainage patterns of the prostate from healthy organs.

Methods: We performed a prospective study (NCT05120973) that included 16 patients who underwent a robot-assisted radical prostatectomy + ePLND + sentinel node (using indocyanine green-Tc-nanocolloid).

View Article and Find Full Text PDF

Context: Adjuvant immune checkpoint inhibitors (ICIs) have recently emerged as guideline-recommended treatments of high-risk muscle-invasive urothelial carcinoma (MIUC). However, there is limited evidence regarding the optimal candidates and the differential efficacy of adjuvant ICI regimens.

Objective: To synthesize and compare the efficacy and safety of adjuvant ICIs for high-risk MIUC using updated data from phase III randomized controlled trials.

View Article and Find Full Text PDF